Previous studies in a mouse model driven by the loss of tumor-suppressive genes (PTEN, TP53, and RB1) reported that FOXA2 plays a key role in the progression of NEPC (39), and in a genetically engineered TRAMP mouse model, FOXA2 expression was uniformly identified in synaptophysin-positive (SYP-positive) tumors (45). This evidence concerns the gene TP53 and neoplasm.